Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol in Dravet syndrome
NL-OMON44663Phase 3Active, not recruiting
- Sponsor
- GW Pharmaceuticals
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in Dravet syndrome (3 arms), sponsored by GW Pharmaceuticals. Primary endpoint: Primary efficacy endpoint. Started Apr 2015; status: active, not recruiting.
02
Drugs
cannabidiol
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NL-OMON44663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44663.